Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2020 • 2019 ACR/ARP Annual Meeting
Metabolic Changes Induced by Anti-Malondialdehyde Antibodies Promote Osteoclast Development
Koji Sakurabas¹, Akilan Krishnamurthy ², Cheng Xu ³, Khaled Amara ⁴, Vivianne Malmström ⁴, Sergiu-Bogdan Catrina ³, Caroline Grönwall ⁴, Bence Rethi ⁵ and Anca Catrina ⁶, ¹Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, stockholm, Sweden, ²Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, Stockholm, ³Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁵Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ⁶Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Malondialdehyde (MDA) is highly reactive compound produced by lipid-peroxidation in situations associated with oxidative stress. MDA can irreversibly modify proteins (e.g. lysine, arginine and histidine…
Abstract Number: 2247 • 2019 ACR/ARP Annual Meeting
Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications
Raj Vachhani¹, Lang Chen ¹, Ronan O'Beirne ², Joshua Melnick ³, Eric Ruderman ⁴, Jeffrey Curtis ¹ and Maria Danila ², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³University of Alabama at Birmingham, Birmimgham, AL, ⁴Northwestern University Feinberg School of Medicine, Division of Rheumatology, Evanston, IL
Background/Purpose: Evidence-based guidelines recommend escalation of therapy in patients with rheumatoid arthritis (RA) with inadequately controlled disease. However, some patients are hesitant to change therapies…
Abstract Number: 2309 • 2019 ACR/ARP Annual Meeting
Clinical Study of Peripheral Blood Lymphocyte Subsets in Patients with Rheumatoid Arthritis Complicated with Osteoporosis
Ting Cheng¹, Sheng-xiao Zhang ², Xiao-qing Liu ¹, Jia Wang ¹, Chong Gao ³ and Xiao-feng Li ¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ²The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), ³Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: Rheumatoid arthritis(RA) is an autoimmune disease mainly manifested by aggressive polyarthritis.The incidence of osteoporosis(OP) has risen and the risk of fracture has further increased…
Abstract Number: 2329 • 2019 ACR/ARP Annual Meeting
Do Myocardial Inflammation and Microvascular Dysfunction in RA Lead to Adverse Changes in Left Ventricular Structure and Function over Time? A Longitudinal Analysis of Participants from Rheumatoid Arthritis: Study of the Myocardium
Rabia Iqbal¹, Elizabeth Park ², Seitetsu Lee ³, Isabelle Amigues ⁴, Christopher Depender ², Afshin Zartoshti ², Jon Giles ⁵, Sabahat Bokhari ⁶ and Joan Bathon ⁵, ¹Division on Rheumatology, Columbia University, Philadelphia, PA, ²Division on Rheumatology, Columbia University, New York, NY, ³Division of Cardiology, Columbia University, New York, NY, ⁴National Jewish Health, Denver, CO, ⁵Division of Rheumatology, Columbia University, New York, NY, ⁶Division of Cardiology and Nuclear Cardiology Laboratory, Columbia University, New York, NY
Background/Purpose: The risk of developing heart failure (HF) in RA patients as compared with non-RA subjects is significantly higher even when adjusted for traditional cardiovascular…
Abstract Number: 2350 • 2019 ACR/ARP Annual Meeting
Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis
Jeffrey Curtis¹, Fenglong Xie ², Cynthia Crowson ³, Brent Mabey ⁴, Darl Flake ⁴, Richard Bamford ⁴, Cheryl Chin ⁴, Eric Sasso ⁵, Elena Hitraya ⁵, Alexander Gutin ⁴ and Jerry Lanchbury ⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³Mayo Clinic Rochester, Rochester, ⁴Myriad Genetics, Inc, South San Francisco, CA, ⁵Crescendo Bioscience, South San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) patients are at elevated risk for cardiovascular (CV) events, but efficient risk stratification based on CV prediction models is not part…
Abstract Number: 2375 • 2019 ACR/ARP Annual Meeting
Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports
Hiroaki Matsuno ¹, Tatsuya Atsumi ², Shuji Takei ³, Naoto Tamura ⁴, Masayoshi Harigai ⁵, Takao Fujii ⁶, Shigeki Momohara ⁷, Yuko Takahashi ⁸, Nobuhiro Narii ⁸, Naoto Tsujimoto ⁸, Atsushi Nishikawa ⁸, Taeko Ishii⁸, Kazuhiko Yamamoto ⁹, Masataka Kuwana ¹⁰ and Michiaki Takagi ¹¹, ¹Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ²Hokkaido University, Sapporo, Japan, ³Kagoshima University, Kagoshima, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁵Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁶Wakayama Medical University, Wakayama, Japan, ⁷Hakkeikai Incorporated Medical Institution, Shizuoka, Japan, ⁸Eli Lilly Japan K.K., Kobe, Japan, ⁹Riken Center for Integrative Medical Sciences, Kanagawa, Japan, ¹⁰Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ¹¹Yamagata University Faculty of Medicine, Yamagata-shi, Japan
Background/Purpose: Baricitinib (bari), is an oral, selective inhibitor of Janus kinase (JAK) 1/ and JAK 2, is used to treat moderately to severely active RA…
Abstract Number: 2407 • 2019 ACR/ARP Annual Meeting
The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis
Kunihiro Yamaoka¹, Yoshiya Tanaka ², Hideto Kameda ³, Barbara Hendrickson ⁴, Sebastian Meerwein ⁵, Ying Zhang ⁴ and Tsutomu Takeuchi ⁶, ¹Kitasato University School of Medicine, Kanagawa, Japan, Kanagawa, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Toho University, Tokyo, Japan, Tokyo, Japan, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁶Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Upadacitinib (UPA) is an oral reversible JAK inhibitor engineered for greater selectivity for JAK1 versus JAK2, JAK3, and TYK2, and is currently being assessed…
Abstract Number: 2825 • 2019 ACR/ARP Annual Meeting
Provider Variability in Glucocorticoid Prescribing for Patients with Rheumatoid Arthritis and Impact on Chronic Glucocorticoid Use
Michael George¹, Joshua Baker ², Lang Chen ³, Qufei Wu ², Fenglong Xie ⁴, Huifeng Yun ³ and Jeffrey Curtis ³, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham
Background/Purpose: Glucocorticoids are recommended as short-term bridging therapy in patients with rheumatoid arthritis (RA), but as many as 30-40% of patients remain on glucocorticoids chronically.…
Abstract Number: 51 • 2019 ACR/ARP Annual Meeting
Cigarette Smoking Has Different Impacts on ACPA and RF Production Depending on Shared Epitope Allele Status in Japanese RA Patients; A Study with the Two Independent Japanese Cohorts (IORRA and KURAMA)
Yuki Ishikawa¹, Motomu Hashimoto ², Katsunori Ikari ³, Koichiro Ohmura ⁴, Masao Tanaka ⁴, Hiromu Ito ⁴, Atsuo Taniguchi ³, Hisashi Yamanaka ³, Tsuneyo Mimori ⁴ and Chikashi Terao ⁵, ¹Joslin Diabes Center, Boston, MA, ²Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Tokyo Women’s Medical University, Tokyo, Japan, ⁴Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵RIKEN, Tokyo, Japan
Background/Purpose: In rheumatoid arthritis (RA), cigarette smoking affects both rheumatoid factor (RF) and anti-citrullinated cyclic peptide/protein antibody (ACPA) production, but its association in relation to…
Abstract Number: 184 • 2019 ACR/ARP Annual Meeting
No Increased Risk of Incidence Diabetes in Patients with Rheumatoid Arthritis Compared to Patients Without RA
Yinzhu Jin ¹, Sarah Chen ², Jun Liu ¹, Rishi Desai ³ and Seoyoung C. Kim¹, ¹Brigham and Women’s Hospital and Harvard Medical School, Boston, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Brigham and Women's hospital, Boston
Background/Purpose: Some previously published studies suggest that patients with rheumatoid arthritis (RA) are at an increased risk of developing diabetes mellitus. We examined the risk…
Abstract Number: 260 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Associated with Longer Hospital Stays in Patients Admitted with Venous Thromboembolism: A Nationwide Analysis 2010-2014
Shraddha Jatwani¹, Karan Jatwani ² and Karan Chugh ¹, ¹St. Vincent Evansville, Evansville, ²Mount Sinai West - St Luke’s Hospital, New York
Background/Purpose: Venous thromboembolism (VTE) is a major health problem and can be potentially fatal when complicated by lethal pulmonary embolism (PE). Previous hospital-based studies have…
Abstract Number: 443 • 2019 ACR/ARP Annual Meeting
Validation of a Risk Perception Questionnaire Developed for Patients with Rheumatoid Arthritis
Irazú Contreras-Yáñez ¹, Pilar Lavielle ², Patricia Clark ³ and Virginia Pascual-Ramos¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Distrito Federal, Mexico, ²Clinical Epidemiology Unit, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Mexico City, Mexico, ³Head of the Clinical Epidemiology Unit, Hospital Infantil de México Federico Gómez-Facultad de Medicina UNAM, Mexico City, Mexico
Background/Purpose: Treatment recommendations directed to rheumatoid arthritis patients (RA) may be more easily adopted if they are patient-centered. The adoption of health behaviors is associated…
Abstract Number: 468 • 2019 ACR/ARP Annual Meeting
Effect of Body Mass Index on the Disease Activity of Patients with Rheumatoid Arthritis in a Gender Specific Manner and Association of Respective Serum C – Reactive Protein Levels with the Body’s Inflammatory Status
Shumaila Iqbal¹, Linda Burns ², Joseph Grisanti ² and Cassandra Zhi ³, ¹University at Buffalo, Sisters of Charity Hospital, Buffalo, ²Buffalo Rheumatology and Medicine, Buffalo, ³Dexel University College of Medicine, Philadelphia, PA
Background/Purpose: Current literature evaluating the effect of high Body Mass Index (BMI) on the disease activity of patients with rheumatoid arthritis (RA) is mixed as…
Abstract Number: 505 • 2019 ACR/ARP Annual Meeting
Low-grade Total Rheumatoid Arthritis MRI Scoring System Can Predict Successful Half-dose Reduction of MTX in Patients with RA in Clinical Remission
Takeshi Suzuki¹, Marina Uchida ², Shoshi Shinagawa ², Machiko Mizushima ³, Takayasu Ando ³, Yutaka Gotou ³, Tomohiko Shibata ² and Kimito Kawahata ⁴, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Division of Rheumatology, Department of Internal Medicine, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan, ³Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ⁴Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan
Background/Purpose: It has been recommended that tapering csDMARDs should be considered if a patient is in persistent remission. However, methods for tapering csDMARDs, including MTX,…
Abstract Number: 628 • 2019 ACR/ARP Annual Meeting
Pain Perception and Opiate Use Among Patients with Inflammatory Arthritis
Alexis Ogdie¹, Sofia Pedro ² and Kaleb Michaud ³, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Pain is the most common symptom among patients with inflammatory arthritis (IA) and residual pain is common in patients IA despite appropriate treatment. Opiate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].